China Economic Net, Beijing, March 14 Junshi Biosciences (688180.SH) recently released the announcement of its 2024 annual performance report. In 2024, the company will achieve operating income of 1948.3173 million yuan, a year-on-year increase of 29.67%; net profit attributable to owners of the parent company was -1282.2792 million yuan, compared with -2283.4319 million yuan in the same period of the previous year; The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was -1256.1027 million yuan, compared with -2297.5588 million yuan in the same period of the previous year. 

From 2016 to 2023, the company's operating income will be 5.9391 million yuan, 54.4998 million yuan, 2.9276 million yuan, 775 million yuan, 1.595 billion yuan, 4.025 billion yuan, 1.453 billion yuan, and 1.503 billion yuan respectively, and the net profit attributable to shareholders of listed companies will be -135 million yuan, -317 million yuan, -723 million yuan, -747 million yuan, -1.669 billion yuan, -721 million yuan, -2.388 billion yuan, - 2.283 billion yuan, net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses were -160 million yuan, -300 million yuan, -706 million yuan, -776 million yuan, -1.709 billion yuan, -884 million yuan, -2.450 billion yuan, -2.298 billion yuan. 

Junshi Biosciences was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on July 15, 2020, with an issue quantity of 87.13 million shares and an issue price of RMB 55.50 per share. 

On the first day of listing, the share price of Junshi Biosciences was as high as 220.40 yuan, and since then, the stock has fluctuated and declined, and the stock is currently in a state of breakage. 

The total amount of funds raised in the initial offering of Junshi Biosciences was 4.836 billion yuan, and after deducting the issuance expenses, the net amount of funds raised was 4.497 billion yuan, which was 1.797 billion yuan more than the original plan. According to the prospectus released by Junshi Biosciences on July 8, 2020, the company plans to raise 2.700 billion yuan, which will be used for innovative drug research and development projects, Junshi Biosciences industrialization Lingang projects, repayment of bank loans and replenishment of working capital. 

The listing and issuance expenses of Junshi Biosciences were 339 million yuan, of which the sponsor CICC and the joint lead underwriters Guotai Junan Securities and Haitong Securities received 320 million yuan in sponsorship and underwriting fees, Rongcheng Certified Public Accountants (special general partnership) received 5.90 million yuan in audit, evaluation and capital verification fees, and Beijing Jia Yuan Law Firm received 6.165 million yuan in lawyer fees. 

In 2022, Junshi Biosciences issued A-shares to specific targets to raise funds. According to the "Reply on Agreeing to the Registration of Shanghai Junshi Biomedical Technology Co., Ltd. to Issue Shares to Specific Targets" (Zheng Jian Xu Xu [2022] No. 2616) issued by the China Securities Regulatory Commission, the Company was approved to issue 70 million RMB ordinary shares to specific targets at an issue price of RMB 53.95 per share, raising a total of RMB 3,776,500,000.00; After deducting the total issuance expenses of RMB31,697,205.06 (excluding VAT), the actual net proceeds amounted to RMB3,744,802,794.94. The actual amount received was RMB3,759,350,000.00, including other outstanding issuance expenses of RMB14,547,205.06. The above-mentioned funds have been in place on November 23, 2022, and Rongcheng Certified Public Accountants (Special General Partnership) has verified the funds in place for the company's issuance of shares to specific objects, and issued the "Capital Verification Report" of Rongcheng Yanzi [2022] No. 230Z0337 on November 24, 2022. After the raised funds are received, they have all been deposited in the special account for raising funds opened by the company. 

According to statistics, Junshi Biosciences raised a total of 8.613 billion yuan in two times.